Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | PPM1B | O75688 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16199052 | 1.00 | POLB (0.68) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL22947121 | 1.00 | POLB (0.68) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL1756845 | 1.00 | POLB (0.68) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL15400303 | 1.00 | POLB (0.68) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL26003315 | 1.00 | POLB (0.68) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL22947120 | 1.00 | POLB (0.68) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL19258989 | 0.92 | POLB (0.57) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL16199396 | 0.92 | POLB (0.57) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL15400698 | 0.92 | POLB (0.57) | POLBAPEX1TDP1PPM1BPTPN1 | |
| SCHEMBL9977663 | 0.92 | POLB (0.57) | POLBAPEX1TDP1PPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440051-B1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RES TRIANGLE INST (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-108727369-B | Influenza virus replication inhibitors and uses thereof | 广东东阳光药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-3362451-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-109153635-B | Neuropeptide S receptor (NPSR) agonists | 研究三角协会 | 2022-04-08 | — | — | CN | disclosed |
| CN-110446711-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2021-10-12 | — | — | US | disclosed |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | ZC3HAV1, MAVS, POLRMT | POLB 35/4885APEX1 4077/4885TDP1 2657/4885 |
| US-20090258893-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | POLB 4271/4885APEX1 3755/4885TDP1 4795/4885 |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | POLB 2527/4885APEX1 4327/4885TDP1 2838/4885 |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | POLB 12/4885APEX1 3263/4885TDP1 2365/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | POLB 4268/4885APEX1 3765/4885TDP1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.